Veterinary Oncology Market Size, Share, Growth Analysis, By Therapy(Surgery, Radiotherapy, Chemotherapy, Immunotherapy), By Animal type(Canine, and Feline), By Cancer Type(Lymphoma, Mast Cell Cancer, Mammary and Squamous Cell Cancer, and Others), By Region - Industry Forecast 2024-2031

The market for veterinary oncology is seeing intense competition as a result of the availability of oncology treatments for veterinary use from numerous large pharmaceutical and medical device businesses. To expand their revenue share and establish their presence, market participants are concentrating on putting new tactics into practice, such as regional growth, mergers, acquisitions, the introduction of new products, collaborations, and distribution agreements. Following Elanco's acquisition of Aratana Therapeutics in, the corporation announced the creation of a commercial team focused on the veterinary specialty market.

Additionally, in the same year, PharmAust in Australia began a Phase 2 clinical trial with their top veterinary medication candidate, monepantel, to treat canine cancer. This was another contribution from the market player. As a repurposed anti-cancer medication for veterinary cancer, PharmAust patented & reformulated monepantel and intends to enter into a deal with Elanco for this application. As a result, the company's development will be sped up by the modification of these types of medications for veterinary oncology therapy, which will also spur market expansion.

Top Player’s Company Profiles

• Zoetis

• Elanco Animal Health

• IDEXX Laboratories

• Veterinary Cancer Group

• Ethos Veterinary Health

• VCA (Veterinary Centers of America)

• BluePearl Veterinary Partners

• Anivive Lifesciences

• Aratana Therapeutics (Part of Elanco Animal Health)

• Oncolytics Biotech Inc.

• VetDC

• Rhizen Pharmaceuticals

• AB Science

• VetCell Therapeutics

• Vet-Stem, Inc.

• Nexvet (Part of Zoetis)

• Pegasus Laboratories (Part of Merck Animal Health)

• Biomedica Management Corporation

• Sentinel Biomedical

• Karyopharm Therapeutics